Capricor Therapeutics prices ~$75M public offering of 4.4M shares at $17/sh

CAPRICOR THERAPEUTICS, INC.

Gross proceeds ~$75M from 4,412,000 shares at $17.00/sh; underwriters have 30-day option for up to 661,800 additional shares.
Offering expected to close October 18, 2024; Piper Sandler and Oppenheimer act as joint book-running managers.
Net proceeds to fund continued product candidate development, manufacturing, working capital, and general corporate purposes.
Offering made under effective Form S-3 shelf registration; prospectus supplement filed October 16, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.